WOCBP must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized
Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy during the study and for at least  months after the last dose of study drugs in such a manner that the risk of pregnancy is minimized. Men on study also must be using contraception. Women of childbearing potential (WOCBP) are women who have not been postmenopausal greater than  year or undergone a hysterectomy or bilateral oophorectomy.
Men and women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study, and for women at least  weeks after the last dose of investigational product and for men at least  weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized
Men and women of childbearing potential (WOCBP) must be using  reliable methods of contraception to avoid pregnancy throughout the study for a period of at least  days before and  days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized
Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  months after the last dose of investigational product in such a manner that the risk of pregnancy is minimized; men on study and for at least  months after the last dose of nab-paclitaxel also must be using contraception; women of childbearing potential (WOCBP) are women who have not been postmenopausal greater than  year or undergone a hysterectomy and/or bilateral oophorectomy
Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least  weeks after ipilimumab is stopped; sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the study
Women of childbearing potential (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized
Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study [and for up to  weeks after the last dose of investigational product] in such a manner that the risk of pregnancy is minimized
Women of childbearing potential (WOCBP) must be using at least one highly effective or two effective accepted methods of contraception to avoid conception throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least  month before start of therapy, and while women are on study for up to  months after T cell infusion and/or at least  months after the study agents LV or CMB are stopped. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal.
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least  month before start of therapy, and while women are on study for up to  months after T cell infusion, and at least  weeks after the study drug is stopped.
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized; suggested precautions should be used to minimize the risk or pregnancy for at least  month before start of therapy, and while women are on study for at least  weeks after pembrolizumab is stopped; WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal; acceptable forms of birth control include condom, diaphragm, hormonal, intrauterine device (IUD), or sponge plus spermicide; abstinence is also an acceptable form of birth control
WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of ipilimumab or HDI, in such a manner that the risk of pregnancy is minimized; women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential \r\n* Men of fathering potential and WOCBP must be using an adequate method of contraception to avoid conception/pregnancy throughout the study and for up to  weeks after the last dose of ipilimumab or HDI in such a manner that the risk of pregnancy is minimized; men or WOCBP who are unwilling or unable to strictly follow this requirement are not eligible\r\n* WOCBP are not eligible if they satisfy any of the following:\r\n** A positive pregnancy test at baseline\r\n** Pregnant or breastfeeding
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of study drug to minimize the risk of pregnancy; WOCBP must have a negative serum or urine pregnancy test within  hours before the start of the investigational product
Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least  months after the last dose of ipilimumab in such a manner that the risk of pregnancy is minimized
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of investigational product; men on study also must be using contraception
Men and women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least  weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least  month before start of therapy, and while women are on study for up to  months after completion of the study. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal.
Negative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for  months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of study drug to minimize the risk of pregnancy
Sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the study
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized; suggested precautions should be used to minimize the risk of pregnancy for at least  month before start of therapy, and while women are on study for up to  months after T cell infusion, and at least  weeks after the study drug is stopped; WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal
COHORT A: Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to  weeks after the last dose of ipilimumab) in such a manner that the risk of pregnancy is minimized
COHORT B: Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to  weeks after the last dose of ipilimumab) in such a manner that the risk of pregnancy is minimized
Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to  weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized
Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to  weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized
Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least  months after ipilimumab/nivolumab is stopped ( months for men)\r\n* Sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab/nivolumab; if the pregnancy test is positive, the patient must not receive ipilimumab/nivolumab and must not be enrolled in the study
Women of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for  weeks prior to screening, during and at least  months after the last dose of trial medication.
Negative serum or urine pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for  months or no previous surgical sterilization, within one week prior to initiation of treatment; WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to  weeks after the last dose of study drug to minimize the risk of pregnancy
Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least  weeks prior to initiation of dosing, and for at least  days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized
Sexually active WOCBP must use an effective method of birth control during the course of study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the study
Subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for at least  weeks after the last dose of study drug to minimize the risk of pregnancy
Women of childbearing potential (WOCBP) must be willing to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized